LEXICON PHARMACEUTICALS, INC.

(LXRX)
  Report
Delayed Nasdaq  -  04:00 2022-08-12 pm EDT
3.170 USD   +14.86%
08/12Lexicon Pharmaceuticals Shares Rise After Piper Sandler Initiates Coverage
MT
08/12Piper Sandler Starts Lexicon Pharmaceuticals at Overweight With $10 Price Target
MT
08/08Lexicon announces full exercise and closing of options to purchase additional shares in connection with previously announced public offering and concurrent private placement
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Lexicon Pharmaceuticals Shares Drop 10% After Trial Results for LX9211

06/30/2022 | 08:52am EDT

By Chris Wack


Lexicon Pharmaceuticals Inc. shares fell 10% to $2.01 after the company reported top-line results of its Phase 2 proof-of-concept study of LX9211 in painful diabetic neuropathy.

The company said LX9211 achieved the primary endpoint of the study, demonstrating a statistically significant reduction in the average daily pain score. Some adverse events were reported at the higher dose, including dizziness, headache and nausea. Nearly all adverse events were reported as mild or moderate.

There were no drug-related serious adverse events reported in the study.

LX9211 is an orally delivered, selective small molecule inhibitor of AAK1, which preclinical studies have shown to reduce pain behavior in models of neuropathic pain without affecting opiate pathways.

LX9211 has received fast track designation from the U.S. Food and Drug Administration for the development in diabetic peripheral neuropathic pain.


Write to Chris Wack at chris.wack@wsj.com


(END) Dow Jones Newswires

06-30-22 1052ET

All news about LEXICON PHARMACEUTICALS, INC.
08/12Lexicon Pharmaceuticals Shares Rise After Piper Sandler Initiates Coverage
MT
08/12Piper Sandler Starts Lexicon Pharmaceuticals at Overweight With $10 Price Target
MT
08/08Lexicon announces full exercise and closing of options to purchase additional shares in..
AQ
08/05Lexicon Announces Full Exercise and Closing of Options to Purchase Additional Shares in..
AQ
08/03LEXICON PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condit..
AQ
08/02TRANSCRIPT : Lexicon Pharmaceuticals, Inc., Q2 2022 Earnings Call, Aug 02, 2022
CI
08/02LEXICON : Q2 Earnings Snapshot
AQ
08/02LEXICON PHARMACEUTICALS : REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSIN..
PU
08/02Lexicon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Busi..
AQ
08/02Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six M..
CI
More news
Analyst Recommendations on LEXICON PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -96,8 M - -
Net Debt 2022 - - -
P/E ratio 2022 -5,49x
Yield 2022 -
Capitalization 614 M 614 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 41 257 039x
Nbr of Employees 87
Free-Float 98,7%
Chart LEXICON PHARMACEUTICALS, INC.
Duration : Period :
Lexicon Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LEXICON PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 3,17 $
Average target price 13,00 $
Spread / Average Target 310%
EPS Revisions
Managers and Directors
Lonnel Coats Chief Executive Officer & Director
Jeffrey L. Wade President & Chief Financial Officer
Raymond Debbane Chairman
Craig B. Granowitz Chief Medical Officer & Senior Vice President
Frank P. Palantoni Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LEXICON PHARMACEUTICALS, INC.-19.54%614
GILEAD SCIENCES, INC.-13.29%78 912
VERTEX PHARMACEUTICALS34.12%75 532
REGENERON PHARMACEUTICALS, INC.-0.45%67 214
WUXI APPTEC CO., LTD.-20.10%40 830
BIONTECH SE-37.80%38 968